TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24080992

Group type: EXPERIMENTAL
Intervention: Zoledronic acid, 4 mg, concurrently with the start of RT and then every six months for a total of 6 infusions (Arm 1)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Observation (Arm 2)
Number of subjects: 96
Study: 21484236

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Drug-related mood induction
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neutral mood induction
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy control individuals
Number of subjects: 42
Study: 18201783

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Successful cardioversion
Number of subjects: 171

Group type: COMPARATOR
Intervention: Unsuccessful cardioversion
Number of subjects: 171
Study: 17143195

Group type: EXPERIMENTAL
Intervention: 500 mg/day RRR-alpha-tocopherol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 500 mg/day mixed tocopherols (60% gamma-tocopherol)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 15138711

Group type: EXPERIMENTAL
Intervention: Continuous infusion etoposide (days 1-6)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bolus infusion etoposide (over 10 h on day 7)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: High-dose etoposide (schedule-dependent)
Number of subjects: 138
Study: 11294082

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (specifics not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study: 9039836

Group type: EXPERIMENTAL
Intervention: Saturated diet (SAT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polyunsaturated diet (POLY)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Monounsaturated diet (MONO)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 9

Group type: COMPARATOR
Intervention: Unfed state
Number of subjects: 9
Study: 8425934

Group type: EXPERIMENTAL
Intervention: Simulated malingering group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RMT and HRD indicators
Number of subjects: 57
Study: 3304790

Group type: EXPERIMENTAL
Intervention: Hexabrix 320 (ioxaglate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niopam 370 (iopamidol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omnipaque 350 (iohexol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2087150

Group type: EXPERIMENTAL
Intervention: GRF(1-29)NH2 (150 micrograms; i.v.)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 1 ml; i.v.)
Number of subjects: 23
Study: 240205

Group type: EXPERIMENTAL
Intervention: 1.25 mg of lorazepam (orally) as a soporific and premedication
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam (orally) as a soporific and premedication
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lorazepam (both dosages)
Number of subjects: 48
Study: 31269050

Group type: EXPERIMENTAL
Intervention: Treatment (home visits, baby massage, and parenting program)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control
Number of subjects: 233
Study: 28689036

Group type: EXPERIMENTAL
Intervention: 3g edetate disodium-based infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo infusion of 500mL normal saline and 1.2% dextrose
Number of subjects: 26
Study: 25294097

Group type: EXPERIMENTAL
Intervention: Goserelin (GnRH analogue) (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 22
Study: 22658289

Group type: EXPERIMENTAL
Intervention: Client change talk (CT) during brief motivational interventions (BMIs)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Frequency of ability/desire/need to change
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Frequency of ability/desire/need not to change
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Average strength of ability/desire/need
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: CT length
Number of subjects: 127
Study: 20957391

Group type: EXPERIMENTAL
Intervention: Group-based treatment (GT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Individual treatment (IT)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention programme (nutrition and exercise counselling)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal weight children (control group)
Number of subjects: 61
Study: 22253980

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) supplementation (60 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Whey protein (WP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study: 17427144

Group type: EXPERIMENTAL
Intervention: Influenza split vaccine vaccination
Number of subjects: 0
Study: 14969650

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin
Number of subjects: 62
Study: 10932334

Group type: EXPERIMENTAL
Intervention: Brainmachine programs
Number of subjects: 0
Study: 9301444

Group type: COMPARATOR
Intervention: Control group (79 patients)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: HEP group (72 patients)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: HEP/5-FU group (84 patients)
Number of subjects: 199
Study: 8365296

Group type: EXPERIMENTAL
Intervention: Endotoxin (7 mg/L)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Corn dust extract (0.08 ml/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Soybean dust extract (0.08 ml/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: HBSS (control)
Number of subjects: 7
Study: 3484828

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation
Number of subjects: 192

Group type: COMPARATOR
Intervention: Higher amplitude stimulation
Number of subjects: 192
Study: 31564046

Group type: EXPERIMENTAL
Intervention: Short telomeres (200 base pairs shorter)
Number of subjects: 66567

Group type: EXPERIMENTAL
Intervention: Short telomeres (6 alleles)
Number of subjects: 66567
Study: 29653820

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/d)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Cisplatin/pemetrexed (LL3)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine (LL6)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Gefitinib (250 mg/d; LL7)
Number of subjects: 134
Study: 28760215

Group type: EXPERIMENTAL
Intervention: Mail-outs sent on behalf of cardiologist at 4, 8, 20, 32, and 44 weeks post-MI
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Mail-outs plus automated interactive voice response system telephone calls and trained lay health workers' calls
Number of subjects: 2742

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2742

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 2742
Study: 25626910

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy and 360° endolaser therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pars plana vitrectomy and an encircling scleral buckle
Number of subjects: 60
Study: 22964869

Group type: EXPERIMENTAL
Intervention: Dyadic peer support intervention for 6 weeks after surgery
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 129
Study: 21906709

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Conventional stenting (after predilatation)
Number of subjects: 3602
Study: 18412565

Group type: EXPERIMENTAL
Intervention: 8% Aluminium Chlorohydrate (ACH) aqueous solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 4%, 8%, or 12% Aluminium Chlorohydrate (ACH) aqueous solution
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Simulated summer conditions with thermal stimulation during application phase
Number of subjects: 4
Study: 16331608

Group type: EXPERIMENTAL
Intervention: ABCD algorithm
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Cognitive education with photographs (Cog)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Cognitive education with photographs + explanations (Cog-Ex)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: ABCD algorithm under stress (T2)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Cognitive education with photographs (Cog) under stress (T2)
Number of subjects: 255
Study: 12494207

Group type: EXPERIMENTAL
Intervention: Telmisartan (40‐80 mg/day) for 24 weeks
Number of subjects: 24
Study: 9862555

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0, 125, and 375 microg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (125 microg/kg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (375 microg/kg)
Number of subjects: 48
Study: 7877305

Group type: EXPERIMENTAL
Intervention: Acadesine (low-dose and high-dose)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acadesine (in vitro)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adenosine (in vitro)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acadesine
Number of subjects: 34
Study: 2212216

Group type: EXPERIMENTAL
Intervention: Metronidazole (250 mg, three times a day for one week) with scaling and root planing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with scaling and root planing
Number of subjects: 0
Study: 355807

Group type: EXPERIMENTAL
Intervention: Sublingual milk therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Double-blind challenges
Number of subjects: 1
Study: 30656824

Group type: EXPERIMENTAL
Intervention: Therapeutic nadroparin (LMWH)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 30359166

Group type: EXPERIMENTAL
Intervention: Adjunctive ondansetron (8 mg/daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 27288217

Group type: EXPERIMENTAL
Intervention: DTaP5‐HB‐IPV‐Hib Group
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1315
Study: 25052733

Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Closed Reduction and Maxillomandibular Fixation (MMF)
Number of subjects: 56
Study: 22752865

Group type: EXPERIMENTAL
Intervention: Fidaxomicin 200 mg twice daily for 10 days
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Vancomycin 125 mg 4 times daily for 10 days
Number of subjects: 1164
Study: 21071074

Group type: EXPERIMENTAL
Intervention: Mobile phone short message service (SMS) intervention
Number of subjects: 538

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 538
Study: 17579629

Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide (CE); carboplatin AUC 5 IV on day 1 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Number of subjects: 220

Group type: COMPARATOR
Intervention: Split doses of cisplatin plus etoposide (SPE); cisplatin 25 mg/m² IV on days 1-3 and etoposide 80 mg/m² IV on days 1-3, with G-CSF support for 4 courses.
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Carboplatin plus etoposide (CE)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Split doses of cisplatin plus etoposide (SPE)
Number of subjects: 220
Study: 16100444

Group type: COMPARATOR
Intervention: FPG <5.0 mM/L (Group 1)
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: 5.6< or =FPG <6.1 mM/L (Group 3)
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: 6.1< or =FPG <7.0 mM/L (Group 4)
Number of subjects: 2964
Study: 12085177

Group type: EXPERIMENTAL
Intervention: Marimastat (10 mg b.d.)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study: 9449906

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 1% imiquimod cream
Number of subjects: 311

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 311
Study: 8903664

Group type: COMPARATOR
Intervention: Mibefradil 150 mg (acute study)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Verapamil SR 240 mg (acute study)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diltiazem 240 mg (acute study)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg daily (chronic study)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Verapamil SR 240 mg daily (chronic study)
Number of subjects: 18
Study: 2295997

Group type: EXPERIMENTAL
Intervention: Combination of fluoride mouthrinsing and fluoride tablets
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Fluoride tablets (2.2 mg NaF daily)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Fluoride mouthrinsing (0.2% NaF solution weekly)
Number of subjects: 1640
Study: 271588

Group type: EXPERIMENTAL
Intervention: Sodium fluoride jelly (single application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium fluoride jelly (four times continuous daily application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminofluoride jelly (single application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminofluoride jelly (four times continuous daily application)
Number of subjects: 0
Study: 31068298

Group type: EXPERIMENTAL
Intervention: 1 μg/kg sufentanil combined with TAP block
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2 μg/kg sufentanil without TAP block
Number of subjects: 60
Study: 28536417

Group type: EXPERIMENTAL
Intervention: doppel active condition (device turned on with heartbeat-like vibration)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (device turned off)
Number of subjects: 2
Study: 26088180

Group type: EXPERIMENTAL
Intervention: High target pCO2 group (aimed at pCO2 values of 55‐65 mm Hg on days 1‐3, 60‐70 mm Hg on days 4‐6, and 65‐75 mm Hg on days 7‐14)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (target pCO2 40‐50 mmHg on days 1‐3, 45‐55 mm Hg on days 4‐6, and 50‐60 mm Hg on days 7‐14)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: High target pCO2 group
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 362
Study: 23163792

Group type: EXPERIMENTAL
Intervention: Thoughts of death
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoughts of survival
Number of subjects: 0
Study: 23382279

Group type: EXPERIMENTAL
Intervention: Saunders traction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Saunders traction + TENS
Number of subjects: 39

Group type: COMPARATOR
Intervention: TENS only
Number of subjects: 39
Study: 19707744

Group type: EXPERIMENTAL
Intervention: Insulin detemir (0.5 U/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: NPH insulin (0.5 U/kg body weight)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both insulin detemir and NPH insulin
Number of subjects: 18
Study: 18158020

Group type: EXPERIMENTAL
Intervention: 40 mg BCG
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 80 mg BCG
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 120 mg BCG
Number of subjects: 152
Study: 15342159

Group type: EXPERIMENTAL
Intervention: Visual feedback gain (increased)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Visual feedback rehabilitation protocol (enhanced gain)
Number of subjects: 13
Study: 12357261

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator and radiofrequency ablation in addition to antiarrhythmic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study: 10027342

Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg with 5-HT3 antagonists
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg with 5-HT3 antagonists
Number of subjects: 69

Group type: COMPARATOR
Intervention: Medium-dose dexamethasone (8 mg) with 5-HT3 antagonists
Number of subjects: 69
Study: 1801562

Group type: EXPERIMENTAL
Intervention: High self-efficacy group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low self-efficacy group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study: 6357659

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg taken at 1200
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 4
Study: 31905228

Group type: EXPERIMENTAL
Intervention: Typhax 0.5 μg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Typhax 2.5 μg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Typhax 10 μg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Typhim Vi (25 μg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31805104

Group type: EXPERIMENTAL
Intervention: Citric-acid dialysate with dCa1.50 (C1.5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acetic-acid dialysate with dCa1.25 (A1.25)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acetic-acid dialysate with dCa1.50 (A1.5)
Number of subjects: 18
Study: 28638008

Group type: EXPERIMENTAL
Intervention: Pulmonary veins isolation during CABG
Number of subjects: 117

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 117
Study: 27101283

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA injections at weeks 0, 16, and 32
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA injections
Number of subjects: 24
Study: 25002006

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Usual care and psychotherapy
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Usual care and education and psychotherapy
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Usual care and education
Number of subjects: 674
Study: 22198448

Group type: EXPERIMENTAL
Intervention: Asenapine 5 or 10 mg
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 20958294

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injection using the PREEMPT paradigm (both fixed and follow-the-pain sites)
Number of subjects: 0

Group type: COMPARATOR
Intervention: OnabotulinumtoxinA injection
Number of subjects: 0
Study: 18482870

Group type: EXPERIMENTAL
Intervention: DNIC condition (ischemic arm pain)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 57
Study: 15805889

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (subgroup with recurrent/persistent otitis media)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Watchful waiting (subgroup with recurrent/persistent otitis media)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (subgroup diagnosed with otitis media at inclusion)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Watchful waiting (subgroup diagnosed with otitis media at inclusion)
Number of subjects: 300
Study: 14582441

Group type: EXPERIMENTAL
Intervention: Structum
Number of subjects: 373

Group type: COMPARATOR
Intervention: Control (NSAID)
Number of subjects: 373
Study: 10605180

Group type: EXPERIMENTAL
Intervention: Cetrorelix 60 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetrorelix
Number of subjects: 20
Study: 9124627

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Untreated (Control)
Number of subjects: 2
Study: 8204918

Group type: COMPARATOR
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine with methylprednisolone)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: ABVD plus cisplatinum (ABVD-PLT)
Number of subjects: 65
Study: 3541165

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 8
Study: 30193843

Group type: EXPERIMENTAL
Intervention: DHEA administration (100 mg/day for 4 weeks)
Number of subjects: 10
Study: 27072219

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART) - 50 Gy in 25 fractions, six fractions weekly
Number of subjects: 106

Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CRT) - 50 Gy in 25 fractions with weekly cisplatin
Number of subjects: 106
Study: 25566589

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (15 mg, 3 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isobaric bupivacaine (15 mg, 3 mL)
Number of subjects: 60
Study: 22622909

Group type: EXPERIMENTAL
Intervention: Stimulation On
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stimulation Off
Number of subjects: 34
Study: 20447305

Group type: EXPERIMENTAL
Intervention: Agmatine sulfate 2.670 g/day for 14 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 18797833

Group type: EXPERIMENTAL
Intervention: Immediate loading of palatal implants (SB group) within 72 hours of insertion.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional loading of palatal implants (KB group) after a 12-week healing period.
Number of subjects: 16
Study: 15844302

Group type: EXPERIMENTAL
Intervention: Intrapericardial urokinase along with conventional treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional treatment alone (including pericardiocentesis and drainage)
Number of subjects: 94
Study: 12051573

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 1 g
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 2 g
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 3 g
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) 4 g
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) with food
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N) without food
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (N)
Number of subjects: 32